An inflammatory transcriptomic signature in psoriasis associates with future cardiovascular events.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
10
10
2022
accepted:
07
02
2023
pmc-release:
01
07
2024
medline:
14
6
2023
pubmed:
17
3
2023
entrez:
16
3
2023
Statut:
ppublish
Résumé
Psoriasis is an inflammatory skin disease associated with increased cardiovascular (CV) risk, whose pathogenesis is not fully known. We identified a transcriptomic signature in psoriasis and investigated its association with prevalent and future risk of a CV event to understand the connection between psoriasis and CV disease (CVD). Psoriasis patients (n = 37) with a history of moderate-severe skin disease without CVD and 11 matched controls underwent whole blood RNA sequencing. This transcriptomic signature in psoriasis versus controls was evaluated in two CVD cohorts: Women referred for cardiac catheterization with (n = 76) versus without (n = 97) myocardial infarction (MI), and patients with peripheral artery disease (n = 106) followed over 2.5 years for major adverse CV or limb events (MACLE). The association between genes differentially expressed in psoriasis and prevalent and incident CV events was assed. In psoriasis, median age was 44 (IQR; 34-51) years, 49% male and ACC/AHA ASCVD Risk Score of 1.0% (0.6-3.4) with no significant difference versus controls. The median psoriasis area and severity index score (PASI) was 4.0 (IQR 2.9-8.2) with 36% on biologic therapy. Overall, 247 whole blood genes were upregulated and 228 downregulated in psoriasis versus controls (p < 0.05), and 1302 genes positively and 1244 genes negatively correlated with PASI (p < 0.05). Seventy-three genes overlapped between psoriasis prevalence and PASI with key regulators identified as IL-6, IL-1β and interferon gamma. In the CVD cohorts, 50 of 73 genes (68%) identified in psoriasis associated with prevalent MI, and 29 (40%) with incident MACLE. Key regulator transcripts identified in psoriasis and CVD cohorts included SOCS3, BCL3, OSM, PIM2, PIM3 and STAT5A. A whole blood transcriptomic signature of psoriasis diagnosis and severity associated with prevalent MI and incident MACLE. These data have implications for better understanding the link between psoriasis, systemic inflammation and CVD.
Sections du résumé
BACKGROUND
BACKGROUND
Psoriasis is an inflammatory skin disease associated with increased cardiovascular (CV) risk, whose pathogenesis is not fully known.
OBJECTIVE
OBJECTIVE
We identified a transcriptomic signature in psoriasis and investigated its association with prevalent and future risk of a CV event to understand the connection between psoriasis and CV disease (CVD).
METHODS
METHODS
Psoriasis patients (n = 37) with a history of moderate-severe skin disease without CVD and 11 matched controls underwent whole blood RNA sequencing. This transcriptomic signature in psoriasis versus controls was evaluated in two CVD cohorts: Women referred for cardiac catheterization with (n = 76) versus without (n = 97) myocardial infarction (MI), and patients with peripheral artery disease (n = 106) followed over 2.5 years for major adverse CV or limb events (MACLE). The association between genes differentially expressed in psoriasis and prevalent and incident CV events was assed.
RESULTS
RESULTS
In psoriasis, median age was 44 (IQR; 34-51) years, 49% male and ACC/AHA ASCVD Risk Score of 1.0% (0.6-3.4) with no significant difference versus controls. The median psoriasis area and severity index score (PASI) was 4.0 (IQR 2.9-8.2) with 36% on biologic therapy. Overall, 247 whole blood genes were upregulated and 228 downregulated in psoriasis versus controls (p < 0.05), and 1302 genes positively and 1244 genes negatively correlated with PASI (p < 0.05). Seventy-three genes overlapped between psoriasis prevalence and PASI with key regulators identified as IL-6, IL-1β and interferon gamma. In the CVD cohorts, 50 of 73 genes (68%) identified in psoriasis associated with prevalent MI, and 29 (40%) with incident MACLE. Key regulator transcripts identified in psoriasis and CVD cohorts included SOCS3, BCL3, OSM, PIM2, PIM3 and STAT5A.
CONCLUSIONS
CONCLUSIONS
A whole blood transcriptomic signature of psoriasis diagnosis and severity associated with prevalent MI and incident MACLE. These data have implications for better understanding the link between psoriasis, systemic inflammation and CVD.
Identifiants
pubmed: 36924033
doi: 10.1111/jdv.19049
pmc: PMC10334288
mid: NIHMS1890384
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1361-1365Subventions
Organisme : NCATS NIH HHS
ID : TL1 TR001447
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001445
Pays : United States
Organisme : NHLBI NIH HHS
ID : KL2TR001446
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL114978
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35HL14499
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23HL152013
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL159276
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01HL139909
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL098129
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01HL114978
Pays : United States
Organisme : NHLBI NIH HHS
ID : UL1TR001445
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32HL098129
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL152013
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01HL144993
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL144993
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL139909
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001446
Pays : United States
Organisme : NHLBI NIH HHS
ID : TL1TR001447
Pays : United States
Informations de copyright
© 2023 European Academy of Dermatology and Venereology.
Références
Front Cardiovasc Med. 2022 Mar 23;9:818890
pubmed: 35402550
Arterioscler Thromb Vasc Biol. 2020 May;40(5):1340-1351
pubmed: 32131611
Circulation. 2022 Jul 12;146(2):94-109
pubmed: 35652342
Arterioscler Thromb Vasc Biol. 2021 Apr;41(4):1521-1533
pubmed: 33657880
Pharmacol Ther. 2015 Jul;151:41-9
pubmed: 25749412
J Am Coll Cardiol. 2018 Jan 2;71(1):53-65
pubmed: 29301628
BMC Cardiovasc Disord. 2020 Mar 13;20(1):133
pubmed: 32169038
Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):787-798
pubmed: 30760013
Circ Genom Precis Med. 2018 Dec;11(12):e002387
pubmed: 30562118
J Invest Dermatol. 2022 Jun;142(6):1749-1752.e4
pubmed: 34808233
J Cardiovasc Comput Tomogr. 2021 Jul-Aug;15(4):372-379
pubmed: 33390348
J Am Coll Cardiol. 2021 Apr 6;77(13):1670-1680
pubmed: 33795041
Circ Res. 2016 Nov 11;119(11):1242-1253
pubmed: 27654120
Am J Transl Res. 2021 Mar 15;13(3):1422-1431
pubmed: 33841667